This session explored FDA regulatory considerations around naming plant-based foods, focusing on recent draft guidance for labeling plant-based milk alternatives. It also addressed broader implications for naming other plant-based products, the impact of consumer scrutiny and litigation, and best practices for managing risk across the alternative protein sector.
